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Abstract
Background: CRIP1 (cysteine-rich intestinal protein 1) has been found in several tumor types, its prognostic impact
and its role in cellular processes, particularly in breast cancer, are still unclear.
Methods: To elucidate the prognostic impact of CRIP1, we analyzed tissues from 113 primary invasive ductal breast
carcinomas using immunohistochemistry. For the functional characterization of CRIP1, its endogenous expression
was transiently downregulated in T47D and BT474 breast cancer cells and the effects analyzed by immunoblotting,
WST-1 proliferation assay and invasion assay.
Results: We found a significant correlation between CRIP1 and HER2 (human epidermal growth factor receptor 2)
expression levels (p = 0.016) in tumor tissues. In Kaplan Meier analyses, CRIP1 expression was significantly associated with
the distant metastases-free survival of patients, revealing a better prognosis for high CRIP1 expression (p = 0.039).
Moreover, in multivariate survival analyses, the expression of CRIP1 was an independent negative prognostic factor,
along with the positive prognosticators nodal status and tumor size (p = 0.029). CRIP1 knockdown in the T47D and
BT474 breast cancer cell lines led to the increased phosphorylation of MAPK and Akt, to the reduced phosphorylation of
cdc2, and to a significantly elevated cell proliferation in vitro (p < 0.001). These results indicate that reduced CRIP1 levels
may increase cell proliferation and activate cell growth. In addition, CRIP1 knockdown increased cell invasion in vitro.
Conclusions: Because the lack of CRIP1 expression in breast cancer tissue is significantly associated with a worse
prognosis for patients and low endogenous CRIP1 levels in vitro increased the malignant potential of breast cancer cells,
we hypothesize that CRIP1 may act as a tumor suppressor in proliferation and invasion processes. Therefore, CRIP1 may
be an independent prognostic marker with significant predictive power for use in breast cancer therapy.
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Background
Breast cancer is the most common cancer diagnosed
among women in the Western world and is the leading
cause of female cancer death [1]. The determination of the
hormone receptor status (estrogen (ER) and progesterone
(PR)) has become standard practice in the management
of invasive breast cancers and is useful as a prognostic
and predictive factor [2]. Similarly, human epithelial
growth factor receptor 2 (HER2) positivity, which is
observed in approximately 30% of breast cancers, is an
important marker for selecting targeted therapy with the
monoclonal anti-HER2 antibody trastuzumab (Herceptin™)
[2-6]. Because a portion of HER2-overexpressing tumors
is nonresponsive to Herceptin™ therapy, there is a need to
identify additional markers linked to HER receptors and
associated signaling proteins for the development of other
targeted therapeutic treatments.
CRIP1 (cysteine-rich intestinal protein 1) belongs to the
LIM/double-zinc finger protein family and has been shown
to be overexpressed in several tumor types, including
breast, cervical, prostate, pancreatic, and colorectal cancers
[7-11]. However, little is known regarding its prognostic im-
pact and functional role in human cancers. Previous studies
have revealed an association between CRIP1 and HER2
levels in breast cancer cells. In breast cancer cell lines and
human breast cancer tissues, an overexpression of HER2
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was correlated with an overexpression of CRIP1 [4,12,13].
A recent study on an intestinal type of gastric cancer
reported that the overexpression of CRIP1 was an inde-
pendent predictor of shortened survival [14]. Patients with
a high expression of CRIP1 displayed decreased survival
probabilities compared with patients with low expression
levels of CRIP1. Conversely, in osteosarcomas, CRIP1
expression was more frequently found in patients with
long-term survival and without metastases, indicating a
favorable prognostic effect [15].
To date, there is no functional characterization of CRIP1,
and its precise role in cancer cells and its impact in progno-
sis are still unclear. The aim of this study was to analyze
the prognostic impact and functional role of CRIP1 in hu-
man breast cancer. Using FFPE tissues from invasive ductal
breast carcinomas (IDC), we show an association between
CRIP1 expression and histopathological parameters and,
the clinical course of the disease. Additionally, we identified
functional properties of CRIP1 in two permanent breast
cancer cell lines using RNA interference (RNAi).
Results
Association between CRIP1 and immunohistochemical
and histopathological parameters
We found no or low CRIP1 expression in 79 tumors
(37 were negative and 42 were classified as 1+), medium
expression in 20 tumors (classified as 2+) and high CRIP1
expression in 14 tumors (classified as 3+). In breast cancer
tissue, positive and negative staining of CRIP1 was
frequently associated with HER2 staining (Figure 1). A
significant correlation was found between CRIP1 and the
expression of HER2 (p = 0.016), and an inverse correlation
was found between CRIP1 expression and estrogen recep-
tor (ER, p = 0.04). No significant association was identified
between CRIP1 and lymph node status, tumor size,
histological grade, or progesterone receptor expression.
Impact of CRIP1 on the clinical course of patients
In univariate analyses of the distant metastases-free survival
of the patients, a significant positive correlation was found
between CRIP1 expression (p = 0.039) and a more favorable
prognosis for patients with positive CRIP1 expression
(classified 1+ to 3+) (Figure 2A, Table 1). HER2 expression
was not significantly associated with the clinical course of
the disease (p = 0.8). In the tumor cohort analyzed, there
was no significant association between CRIP1 expression
and the lymph node status of the patients. However, when
we considered only lymph node-positive tumors, a trend
was observed between CRIP1 positivity and a better clinical
course of the disease (p = 0.09) (Table 1).
The CRIP1 expression in our tumor cohort was associ-
ated with the expression of HER2 (p = 0.016). Considering
the CRIP1 expression in only HER2-negative tumors
(Table 1), no significant association was found with the
Figure 1 The co-expression of HER2 and CRIP1 in breast cancer tissue. Representative images of breast cancer tissues showing positive or
negative immunohistochemical staining for HER2 and CRIP1, respectively.
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clinical course. However, in HER2-positive tumors, two
different prognostic groups could be identified according to
the CRIP1 expression. CRIP1-positive tumors showed a
better prognosis, with 39% of patients (23 out of 59) suffer-
ing distant metastases compared with 67% (14 of 21) of
CRIP1-negative patients, within the follow-up period of
more than 30 years (p = 0.021) (Figure 2B, Table 1). This
result clearly indicates that CRIP1 expression may be a
useful prognostic marker in HER2-positive tumors.
Remarkably, in multivariate Cox regression analysis,
CRIP1 proved to be an independent prognostic
factor, along with nodal status (pN) and tumor size
(pT) (p = 0.039) (Table 1).
Co-expression of HER2 and CRIP1 in the T47D and BT474
breast cancer cell lines
For functional in vitro analyses, appropriate breast
cancer cell lines were identified that co-expressed both
HER2 and CRIP1 at adequate levels. The adequate co-
expression of both proteins was detected in the T47D,
BT474 and MDA-MB-361 cell lines (out of seven ana-
lyzed breast cancer cell lines) (Figure 3A). In this study,
we selected T47D and BT474 cells for CRIP1 knock-
down and subsequent analyses because in these cells the
protein expression levels of CRIP1 and HER2 were
higher than in the MDA-MB-361 cells.
The downregulation of CRIP1 significantly elevates the
cell proliferation in vitro
After the identification of small interfering RNAs (siRNAs)
that showed specific and efficient CRIP1 downregulation
(Figure 3B and Additional file 1), the effects of CRIP1
knockdown in the T47D and BT474 cells on the expression
and phosphorylation of HER2 signaling-associated proteins
were analyzed using immunoblotting. Following CRIP1
knockdown, no effects were observed for HER2 (human
epidermal growth factor receptor 2), and HER2-related
and proliferation-associated signaling proteins like
MAPK (mitogen-activated protein kinase), STAT3 (signal
CRIP1 
n = 36 (21 events) 
n = 75 (28 events) 
p = 0.039 
CRIP1 scores 1+ to 3+ 
CRIP1 score 0 
n = 59 (23 events) 
n = 21 (14 events) 
p = 0.021 
CRIP1 in HER2-positive tumors (1+ to 3+)
CRIP1 scores 1+ to 3+ 
CRIP1 score 0 
BA
n (total) = 80n (total) = 111
Figure 2 Kaplan Meier survival analysis of the distant metastases-free survival of patients. (A) Patients were grouped according to CRIP1
expression into negative (0) and positive (classified 1+ to 3+) groups. (B) Only patients with HER2-positive tumors were stratified according to
their CRIP1 expression (negative vs. positive).
Table 1 Results from univariate and multivariate survival
analyses for a distant metastases-free survival of breast
cancer patients
CRIP1
negative (0) 36 21 / 58%
positive (1+, 2+, 3+) 75 28 / 37% p = 0.039
CRIP1 in lymph node-negative tumors
CRIP1 negative (0) 23 11 / 48%
CRIP1 positive (1+, 2+, 3+) 44 11 / 25% p = 0.1 n.s.
CRIP1 in lymph node-positive tumors
CRIP1 negative (0) 13 10 / 77%
CRIP1 positive (1+, 2+, 3+) 33 17 / 52% p = 0.09 n.s.
CRIP1 in HER2-negative tumors (0)
CRIP1 negative (0) 14 7 / 50%
CRIP1 positive (1+, 2+, 3+) 14 5 / 36% p = 0.6 n.s.
CRIP1 in HER2-positive tumors (1+, 2+, 3+)
CRIP1 negative (0) 21 14 / 67%
CRIP1 positive (1+, 2+, 3+) 59 23 / 39% p = 0.021





tumor size 0.51 4.58 0.03
CRIP1 −0.66 4.28 0.039 * total p = 0.029
*inverse correlation, Significant p-values are in bold.
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transducer and activator of transcription 3), Akt, cdk2
(cyclin dependent kinase 2) or PTEN (phosphatase and
tensin homologue deleted on chromosome ten) protein
expression levels (Figure 4A). In contrast, the phosphoryl-
ation of MAPK at Thr202/Tyr204 was increased in both
cell lines due to CRIP1 downregulation (Figure 4A).
This mitogen-activated protein kinase is involved in cell
proliferation, differentiation and growth [16]. Phosphory-
lated MAPK activates the downstream phosphorylation of
its substrates in the cytoplasm, or it translocates to the
nucleus and subsequently regulates gene expression through
the phosphorylation of transcription factors. p38 MAPK
regulates cell survival and apoptosis [16]. The phos-
phorylation of p38 MAPK at Thr180/Tyr182 leads to
the activation of other MAPK and transcription factors
that also regulate apoptosis. CRIP1 knockdown did not
lead to an altered phosphorylation of p38 MAPK (data
not shown). Akt activation leading to the regulation of
survival and apoptosis is regulated by phosphorylation at
Thr308 and Ser473 [17]. CRIP1 knockdown led to an
increased phosphorylation of Akt at Thr308 (Figure 4A).
The phosphatase PTEN is a tumor suppressor that
negatively regulates the PI3K/Akt pathway [18]. The
phosphorylation of PTEN impairs its tumor suppressive
function. CRIP1 silencing did not affect the phosphoryl-
ation of PTEN (data not shown).
STAT3 drives cell growth, survival, differentiation and
gene expression via phosphorylation at Tyr705. The
phosphorylation at Ser727 is associated with its role as a
transcription factor [19]. After the siRNA-mediated
downregulation of CRIP1, we did not observe an
altered phosphorylation of STAT3 at Ser727, but the
phosphorylation at Tyr705 was elevated in T47D
cells (Figure 4A), in BT474 cells this phosphorylation
site was not detectable. We further analyzed the
expression and phosphorylation of cell cycle proteins
in response to changes in CRIP1 expression. No
altered expression was observed for cyclin E, cyclin
D1, cyclin A proteins or the cyclin-dependent kinase
2 (data not shown). However, we observed a reduced
phosphorylation of cdc2 at Tyr15 in both cell lines
following CRIP1 silencing (Figure 4A).
In addition, we investigated the proliferation of T47D
and BT474 cells following CRIP1 knockdown based on
the enzymatic cleavage of tetrazolium salts into
formazan (WST-1 proliferation assay). Compared with
control cells (mock and cells transfected with siRNA
targeting GAPDH) the proliferation was significantly
elevated of approximately 40% when T47D cells were
depleted of CRIP1 using the most efficient siRNA1
(Figure 4B). In BT474 cells, in both silencing approaches
the proliferation index was elevated of over 40% or 60%,
respectively (Figure 4B).
CRIP1 silencing enhances the invasion of breast
cancer cells
To further elucidate the functional role of CRIP1 in
breast cancer, we analyzed the migration or invasion of
transfected and control T47D and BT474 breast cancer
cells. Due to a non-confluent cell formation, the BT474
cells are not suitable for a wound scratch assay. The
migration of T47D cells was not affected by reduced
CRIP1 protein levels (data not shown). In contrast,
compared with control cells, the invasion of T47D cells was
2.7 fold higher after knockdown of the CRIP1 protein using
the most efficient siRNA1 (Figure 5A). In addition, the
invasion of BT474 cells was also elevated (approximately
2.3 fold higher) following CRIP1 knockdown. To further
confirm this observation, we determined the activation of
MMP9 (matrix metalloproteinase 9) with the immunoblot-
ting of the supernatants of serum-starved cells. The activa-
tion of MMP9 (illustrated by the band at 84 kDa) was
slightly increased following CRIP1 silencing in T47D cells
(Figure 5B). In the BT474 cell line, the MMP9 protein was
not detectable.
Discussion
CRIP1 was first identified in the mouse small intestine
through its pattern of developmental regulation during
the neonatal period [20]. It is a member of the LIM/
double-zinc finger protein family and is a developmen-
tally regulated protein that appears to play a role in
protein-protein interactions during transcriptional pro-
cesses [21-23]. Members of the LIM zinc-finger protein
Figure 3 CRIP1 protein levels in breast cancer cell lines and
after transient downregulation in T47D cells. (A) Western blot
analysis of HER2 and CRIP1 expression in seven breast cancer cell
lines using antibodies targeting HER2, CRIP1 and tubulin (loading
control). (B) Western blot analysis of CRIP1 expression in
nontransfected T47D cells (mock) and transiently transfected T47D
cells using four different siRNAs and siRNAGAPDH (positive control).
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family are thought to play a role in the growth and dif-
ferentiation of eukaryotic cells [24,25]. CRIP1 has also
been suggested to play a role in the host defense system,
and the differential expression of CRIP1 can alter cyto-
kine patterns and the immune response in transgenic
mice [24]. The overexpression of CRIP1 has been ob-
served in several human malignant tumors, including
cervical cancer, breast cancer, prostate cancer, colorectal
cancer, pancreatic cancer, gastric cancer and osteosar-
coma [7-11,13-15]. However, no agreement has been
reached regarding the results obtained from the tumors
of different entities, and the functional role of CRIP1 is
still unclear.
In breast cancer, a role for CRIP1 was proposed in
HER2-related oncogenesis because the upregulation of
CRIP1 was recorded in HER2-overexpressing carcin-
omas of the breast [4], which indicates an indirect prog-
nostic effect of CRIP1. Furthermore, Rauser et al.
confirmed these results using mass spectrometry by
identifying CRIP1 expression in HER2-positive breast
Figure 4 CRIP1 silencing results in the activation of signaling proteins involved in cell proliferation. (A) Western blot analysis showing the
expression and phosphorylation levels of signaling proteins after the knockdown of CRIP1 in T47D and BT474 breast cancer cells using HER2,
(phospho) MAPK, (phospho) STAT3, (phospho) Akt and (phospho) cdc2 antibodies. Tubulin was used as a loading control. The mean values of three
independent experiments are shown. (B) Seventy-two hours after transfection, the WST-1 reagent was added to a defined amount of T47D and BT474
cells and the absorbance measured after 3 h is shown. The graph represents the amount of viable cells in relation to the mock control. The means of
five independent experiments, the standard deviations and the p-values are shown. For statistical analyses, the student´s t-test was performed.
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tumors [13]. In our study on primary breast carcinomas,
CRIP1 expression that was detected by IHC was not
significantly correlated with HER2 expression. However,
regarding the distant metastases-free survival of patients,
we demonstrated a more favorable clinical course for
HER2-positive tumors that expressed CRIP1 compared
with HER2-positive tumors lacking CRIP1.
To the best of our knowledge, a positive association
between CRIP1 and the distant metastases-free survival of
breast cancer patients has not been described previously.
Here, we show that patients with CRIP1-expressing
tumors have a more favorable prognosis compared with
patients with CRIP1-negative tumors. Moreover, we show
that CRIP1 expression in breast carcinomas is of inde-
pendent (inverse) prognostic value in multivariate survival
analyses in addition to lymph node status and tumor size.
Baumhoer et al. also found a favorable clinical course for
patients with CRIP1 expression in osteosarcoma [15],
which fully corresponds to our results in breast carcin-
omas. However, the inverse prognostic relevance of CRIP1
expression that we identified in our tumor cohort is not in
agreement with results obtained in gastric cancers [14].
Studies in gastric cancers have demonstrated that CRIP1
expression is directly associated with a worse prognosis
for patients.
CRIP1 was also described in breast cancer to be
among a panel of genes relevant to bone metastases
[26,27]. In our study, we did not analyze metastases, only
primary breast tumors, in which CRIP1 expression was
not significantly associated with lymph node metastases
or tumor size. Our in vitro analyses confirm the findings
in metastatic tissues. The invasive behavior of the cells
was strongly elevated following CRIP1 knockdown in
T47D and BT474 cells. Additionally, we confirmed that
the potential for the enhanced invasion of the cells after
CRIP1 knockdown may also be based on the increase in
active MMP (matrix metalloproteinases) 9 levels. MMPs
are key proteins in wound healing, tumor invasion,
angiogenesis and carcinogenesis [28]. A prerequisite for
invasion and thus tumor malignancy is the cleavage of the
precursor protein into the active MMP [29], which, in our
study, was elevated after CRIP1 downregulation.
Latonen et al. found that CRIP1 protein expression
was upregulated as a response to increased cellular
density, indicating a proliferation-reducing activity of
CRIP1 [30]. This observation is in agreement with
our in vitro analyses, suggesting that low CRIP1 protein
levels promote cell proliferation.
To further characterize the function of CRIP1 in
breast cancer, particularly its role in cell signaling and
proliferation processes, we investigated the phosphorylation
status of several signaling molecules (MAPK, STAT3,
PTEN and Akt). These proteins are all essential in
cellular processes, including proliferation, survival, growth,
migration, differentiation and anti-apoptotic pathways
[16,19,31-33]. Following CRIP1 knockdown, we observed
an elevated phosphorylation of MAPK. This kinase pro-
motes proliferation, growth and migration through the
phosphorylation of other key regulators and transcription
factors. Elevated levels of phosphorylated MAPK due to
CRIP1 knockdown could increase the proliferation and
growth of breast cancer cells; however the degree of the
effects were dependent on the respective cell line and used
siRNA. This outcome may correlate with different genetic
features and signaling pathways in the used cell lines.
STAT3 also plays an important role in cell growth, sur-
vival, differentiation and gene expression via phosphoryl-
ation at Tyr705 followed by dimerization, translocation to
the nucleus and DNA binding. STAT3 phosphorylation at
Ser727 is associated with its role as a transcription factor
[19]. Although the latter phosphorylation site was not
affected, increased STAT3 phosphorylation at Tyr705 was
Figure 5 CRIP1 knockdown increases the invasive potential of T47D and BT474 breast cancer cells in vitro. (A) A quantification of the
invasion assay of nontransfected T47D cells or BT474 cells (mock) compared with transiently transfected T47D cells or BT474 cells 48 h post-
transfection (T47D cells) and 72 h post-transfection (BT474 cells). The mean values and standard deviations of two independent experiments are
shown. (B) Western blot analysis showing the expression of cleaved (84 kDa band) MMP9 in supernatants of nontransfected T47D cells (mock)
and T47D cells with transiently downregulated CRIP1 expression using effective siRNAs and siRNAGAPDH (positive control). The mean values of
three independent experiments are shown.
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observed after CRIP1 knockdown in T47D cells. This
outcome indicates an association of CRIP1 with selective
STAT3 activation, and reduced CRIP1 protein levels
increase cell proliferation and survival via STAT3 activation
in vitro.
We also determined the activation of Akt through
phosphorylation at Thr308 and Ser473 using Western
blot analysis. Activated Akt regulates survival and
apoptosis through inhibiting target proteins [17,33].
After CRIP1 knockdown, we observed an increase in
Akt phosphorylation at Thr308 that may cause reduction
in anti-apoptotic signaling. These results indicate that
CRIP1 is associated with Akt.
Because CRIP1 knockdown did not affect the phos-
phorylation of p38 MAPK or PTEN, we conclude that
p38 MAPK- and PTEN-mediated signal transduction is
independent of CRIP1 expression levels.
After CRIP1 knockdown, we also analyzed the in vitro
phosphorylation status of cdc2, a cell cycle protein that is
involved in the entrance into mitosis [34,35]. CRIP1 silen-
cing led to a slight reduction of phosphorylation of cdc2 at
Tyr15 and a consequential increase in the activation of this
cell cycle protein, which again suggests that cell prolifera-
tion increases at low CRIP1 levels. In addition, our Western
blot results were underpinned by significantly increased
proliferation in vitro when CRIP1 was downregulated in
T47D and BT474 breast cancer cells. Recently, Jeschke
et al., also described CRIP1 as a potential prognosticator for
poor overall survival in breast cancer based on the
methylation of CRIP1 gene promoter which may lead
to its silencing [36]. This fully agrees with our study
demonstrating that downregulation of CRIP1 in breast
cancer cell lines rather leads to increased cell prolifer-
ation and invasion and this may also result in a poor
prognosis for breast cancer patients.
In this study, we aimed to further characterize CRIP1
in breast cancer. We identified CRIP1 as an independent
prognostic factor of the metastases-free survival of
breast cancer patients and found that, in HER2-positive
tumors, CRIP1 expression allowed for the identification
of two distinct prognostic groups, with a better prognosis
for patients whose tumors exhibited CRIP1 and HER2
expression. These results show that CRIP1 may serve as
an additional therapeutic and prognostic marker, particu-
larly in HER2-positive tumors. Furthermore, the results of
our in vitro analyses indicate a possible tumor suppressor
role for CRIP1 because its silencing was favorable for
tumor cell proliferation, tumorigenic signaling and the
invasive potential of breast cancer cells.
Conclusions
CRIP1 was shown to be associated with HER2 expression
in breast cancer tumors, but its function is still unclear.
We show that in invasive breast carcinomas, CRIP1
expression is associated with not only HER2 expression
but also the metastases-free survival of patients, with
a more favorable prognosis for patients with high
CRIP1 expression. In HER2-positive tumors, two distinct
prognostic groups could be identified according to their
CRIP1 expression.
The downregulation of CRIP1 in T47D and BT474
breast cancer cells resulted in the activation of signal trans-
duction molecules (MAPK and Akt) and cyclin-dependent
kinase (cdc2) and caused an increase of cell proliferation
and invasion in vitro.
Our results demonstrate that low CRIP1 expression
promotes increased cellular proliferation and the
invasion of cells in vitro and is associated with a
worse prognosis for breast cancer patients. Therefore,




Ethical approval concerning the use of tumor tissues in
this study was obtained from the Ethics Committee of
the Medizinische Fakultät der Technischen Universität,
Munich, Germany. All experimental research described
here was performed on human tissue only and was in
compliance with the Helsinki Declaration. Formalin-
fixed and paraffin-embedded archival material was ran-
domly collected from 113 patients with invasive ductal
breast carcinomas. In total, 67 of the tumors were
node-negative, and most of the tumors (n = 72) were
less than 2 cm in size. According to the histological
grade [37], most of the tumors were classified as
grade 2 (n = 75), 9 as grade 1, and 29 as grade 3. In
addition to the standard histopathological parameters
(lymph node status, tumor size, histological type and
grade), immunohistochemical data from the tumors
were available for HER2 and estrogen and progester-
one receptor. The median follow-up of patients was
134 months (max. 468 months), with 49 (44%) of the
patients showing disease recurrence with distant metasta-
ses within the period of clinical follow-up.
Tissue microarrays
Tissue microarrays (TMAs) were produced as previously
described [38] using a tissue-arraying instrument (Beecher
Instruments Inc., Silver Spring, MD, USA). Hematoxylin-
and eosin-stained sections of the TMAs were examined,
and the original paraffin blocks were re-examined to
validate representative sampling.
Immunohistochemical analyses
Immunohistochemical staining was performed on 3 μm
thick sections of the TMAs using an automated stainer
(Discovery XT) and a DAB Map kit (both Ventana
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Medical Systems, Tucson, AZ, USA). The CRIP1 primary
antibody (AbD Serotec, Oxford, UK) was diluted 1:100, and
the staining intensities were scored by two independent
observers using a 4-point scale as indicated: 0 (no staining)
and from 1+ (light staining) to 3+ (strong staining).
Statistics
The correlations between CRIP1, HER2, and the histo-
pathological parameters were examined with Spearman's
rank correlation test. For univariate survival analyses,
Kaplan Meier curves were calculated, and the differences
between strata were evaluated with the log-rank chi-
squared test. A multivariate analysis was performed
using Cox proportional hazards regression and a stepwise
selection algorithm (SAS Institute, Cary, NC, USA). All of
the parameters showing a significance level of p ≤ 0.15 in
univariate analysis were analyzed with multivariate
analysis. In all of the other tests, statistical significance
was established if p ≤ 0.05.
Cell culture and transient silencing of CRIP1
The human T47D and MCF7 breast cancer cell lines
were maintained in RPMI 1640 (Roswell Park Memorial
Institute) medium. The human BT474, SKBR3, MDA-
MB-231, MDA-MB-361 and JIMT breast cancer cell
lines were maintained in DMEM (Dulbecco’s Modified
Eagle Medium). The media were supplemented with
10% FBS, the antibiotics penicillin and streptomycin
(0.5%), 10 μg/ml human insulin (for the T47D, MCF7
and JIMT-1 cells), and the cells were maintained at 37°C
in 5% CO2. To identify efficient and specific siRNAs for
the knockdown of CRIP1, T47D and BT474 breast
cancer cells were transiently transfected with four differ-
ent siRNAs (Invitrogen, Carlsbad, CA, USA, and Santa
Cruz Biotechnology, Heidelberg, DE) and positive and
negative control siRNAs for 48 h and 72 h, as described
previously [39]. Specific transfections were performed in
three independent experiments.
Western blot analysis
For SDS-PAGE and Western blot analysis, T47D and
BT474 breast cancer cells were treated as described
previously [39]. The proteins were detected with primary
antibodies targeting CRIP1 (AP4707b, Abgent, San
Diego, CA, USA); HER2 (A0485, DAKO, Glostrup, DK);
(phospho, 9554) PTEN (9559), (phospho, 4376) MAPK
(4695), (phospho, 9211) p38 MAPK (9212), phospho-
STAT3 (9131 and 9134), (phospho, 4056) Akt (9272),
phospho-cdc2 (9111), and MMP9 (3852) (Cell Signaling
Technology, Beverly, MA, USA); cdk2 (sc-6248) and
GAPDH (sc-25778) (Santa Cruz Biotechnology, Heidelberg,
DE); STAT3 (610190, BD Transduction Laboratories,
Lexington, KY, USA); and actin (A5441) and tubulin
(T5168, Sigma, St. Louis, MO, USA). Anti-rabbit (NA934)
and anti-mouse (NA931) peroxidase-conjugated secondary
antibodies were obtained from GE Healthcare (Chalfont St.
Giles, Buckinghamshire, UK). All bands showing altered in-
tensities after CRIP1 knockdown were quantified relative to
the control bands using the Molecular Imager ChemiDoc™
XRS and the analysis software Quantity OneW (Bio-Rad
Laboratories, Hercules, CA, USA).
WST-1 cell proliferation assay
Cell proliferation was determined using water-soluble
tetrazolium WST-1 (4-[3-(4-Iodophenyl)-2-(4-nitrophenyl)-
2H-5-tetrazolio]-1,3-benzene disulfonate) for the spectro-
photometric assay according to the manufacturer’s protocol
(05015944001, Roche Diagnostics, Mannheim, DE). One
day after transfection, T47D and BT474 cells were seeded
at a concentration of 1 × 104 cells per well in a 96-well
tissue culture plate. After following 48 h, the WST-1
reagent was added and the cells were incubated for 0.5 h to
4 h at 37°C. The absorbance of the infected and the control
cells was measured against a background control using a
microplate ELISA reader (Bio-Rad, München, DE) at 450
nm (reference wavelength at 655 nm). Five independent
experiments were performed.
Wound scratch migration assay
A migration assay using transiently transfected and
nontransfected T47D breast cancer cells was performed
twice and quantified as described previously [39]. In
brief, a confluent monolayer of T47D cells was scratched
using a 1 mm pipette tip. The cells were washed, and
serum-reduced medium was added at a concentration
(0.1% FBS) that reduced proliferation but was sufficient
to avoid apoptosis or cell detachment [40]. The cells
were incubated at 37°C in 5% CO2 and monitored.
Matrigel invasion assay
Control and transfected T47D and BT474 breast cancer
cells were seeded at a density of 5 × 104 onto BD
BioCoat Matrigel Invasion Chambers (BD, Bedford, MA,
USA) in 24-well cell culture plates and incubated for 24
h (T47D cells) or 48 h (BT474 cells) at 37°C one day
after transfection. For T47D cells, epidermal growth
factor (EGF, 25 ng/ml in serum-reduced medium) was
used as a chemoattractant in the lower chamber. For the
BT474 cells in the lower chamber the complete medium
was used and the invasion assays were performed according
to the manufacturer’s instructions. After incubation, the
non-invading cells were removed from the apical side
of the membrane with a cotton swab. The invading
cells were then fixed with methanol, stained with
toluidine blue, and counted under a microscope. The
assay was performed twice.
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Additional file
Additional file 1: The original Western blots of CRIP1-deleted and
mock T47D cells using antibodies targeting CRIP1, GAPDH and Tubulin.
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